Posted date |
Nonproprietary name
(Click on each drug name for more information
[only in Japanese ]) |
Detailed information on revisions of PRECAUTIONS
(from MHLW) |
Summary of
investigation results
(from PMDA) |
Reference article (Important Safety Information) in Pharmaceuticals and Medical Devices Safety Information (PMDSI) |
March 28, 2024 |
Andexanet alfa (genetical recombination) |
|
|
PMDSI No. 409 |
February 15, 2024 |
Topiramate |
|
|
PMDSI No. 408 |
Nintedanib ethanesulfonate |
|
Appendix: Evaluation of the risk of artery dissection due to systemic exposure to VEGF/VEGFR inhibitors |
|
Axitinib |
Aflibercept beta (genetical recombination) |
Cabozantinib malate |
Sunitinib malate |
Sorafenib tosilate |
Pazopanib hydrochloride |
Vandetanib |
Ponatinib hydrochloride |
Ramucirumab (genetical recombination) |
Regorafenib hydrate |
Lenvatinib mesilate |
Linezolid |
|
|
|
Linezolid |
Itraconazole |
|
|
|
February 8, 2024 |
Adsorbed diphtheria-purified pertussis-tetanus-inactivated polio-Haemophilus type b conjugate combined vaccine (Gobik Aqueous Suspension Syringes) |
|
- |
|
Adsorbed diphtheria-purified pertussis-tetanus-inactivated polio-Haemophilus type b conjugate combined vaccine (Quintovac Aqueous Suspension Injection) |
|
- |
|
January 10, 2024 |
Sertraline hydrochloride |
|
Appendix: Evaluation of the effect of antidepressants on indices of decreased platelet count using MID-NET® |
|
Acetazolamide |
|
|
PMDSI No. 407 |
Acetazolamide sodium |
Cortisone acetate |
|
|
PMDSI No. 407 |
Dexamethasone (oral dosage form) (preparations indicated for multiple myeloma) |
|
Dexamethasone (oral dosage form) (preparations indicated for lymphoid tumours) |
|
Dexamethasone sodium phosphate (injections) |
Hydrocortisone |
Hydrocortisone sodium succinate (preparations indicated for lymphoid tumours) |
Prednisolone (oral dosage form) |
Prednisolone sodium succinate |
Methylprednisolone |
Methylprednisolone sodium succinate |
Methylprednisolone acetate |
Dexamethasone palmitate |
|
Hydrocortisone sodium succinate (preparations not indicated for lymphoid tumours) |
|
Hydrocortisone sodium phosphate |
Prednisolone sodium phosphate |
|
Atezolizumab (genetical recombination) |
|
|
PMDSI No. 407 |
Encorafenib |
|
|
PMDSI No. 407 |
Binimetinib |
Pembrolizumab (genetical recombination) |
|
|
PMDSI No. 407 |
November 24, 2023 |
Nivolumab (genetical recombination) |
|
- |
|
November 21, 2023 |
Metyrapone |
|
|
PMDSI No. 406 |
Apixaban |
|
|
PMDSI No. 406 |
Edoxaban tosilate hydrate |
Dabigatran etexilate methanesulfonate |
Rivaroxaban |
Warfarin potassium |
|
Technetium (99mTc) galactosyl human serum albumin diethylenetriamine
pentaacetic acid |
|
|
PMDSI No. 406 |
October 12, 2023 |
Acetaminophen (oral dosage form) |
|
Appendix 3 is not included. See the detailed information on revisions of PRECAUTIONS. |
|
Acetaminophen (oral dosage form) |
|
Acetaminophen (injections) |
|
|
Acetaminophen (suppository) |
|
|
Tramadol hydrochloride/
acetaminophen |
|
|
Diprophylline/dihydrocodeine
phosphate/dl-methylephedrine
hydrochloride/diphenhydramine salicylate/acetaminophen/
bromovalerylurea |
|
|
October 12, 2023 |
Filgrastim (genetical recombination) |
|
|
- |
Filgrastim (genetical recombination, biosimilar 1) |
- |
Filgrastim (genetical recombination, biosimilar 2) |
- |
Pegfilgrastim (genetical recombination) |
|
- |
Pegfilgrastim (genetical recombination, biosimilar 1) |
- |
Lenograstim (genetical recombination) |
|
- |
Diazoxide |
|
|
- |
Apalutamide |
|
|
PMDSI No. 405 |
Ipilimumab (genetical recombination) |
|
|
- |
Technetium (99mTc) tetrofosmin |
|
|
PMDSI No. 405 |
COVID-19 (SARS-CoV-2) vaccine (recombinant chimpanzee adenovirus vector) |
|
|
- |
Adenosine |
|
|
- |
August 29,
2023 |
Rivastigmine |
|
|
PMDSI No. 404 |
Finasteride |
|
Appendix: Summary of Disproportionality Analysis Using VigiBase |
- |
Dabigatran etexilate methanesulfonate |
|
|
PMDSI No. 404 |
Peficitinib hydrobromide |
|
|
PMDSI No. 404 |
Cefazolin sodium |
|
|
- |
Cefazolin sodium hydrate |
- |
July 20,
2023 |
Atorvastatin calcium hydrate |
|
Appendix: Summary of Disproportionality Analysis Using VigiBase |
PMDSI No. 403 |
Ezetimibe/atorvastatin calcium hydrate |
Ezetimibe/rosuvastatin calcium |
Simvastatin |
Pitavastatin calcium hydrate |
Pitavastatin calcium hydrate/ezetimibe |
Pravastatin sodium |
Fluvastatin sodium |
Rosuvastatin calcium |
Amlodipine basilate/
atorvastatin calcium hydrate |
Tirzepatide |
|
|
- |
Minocycline hydrochloride
(oral dosage form) |
|
|
- |
Minocycline hydrochloride (injections) |
- |
Ensitrelvir fumaric acid |
|
|
- |
June 13,
2023 |
Ipilimumab (genetical recombination) |
|
|
- |
Nivolumab (genetical recombination) |
|
PMDSI No. 402 |
May 30,
2023 |
Haemophilus influenzae type b conjugate vaccine (tetanus toxoid conjugate) |
|
- |
- |
May 9,
2023 |
Azilsartan |
|
|
PMDSI No. 401 |
Azilsartan |
Azilsartan/amlodipine besilate |
Alacepril |
Aliskiren fumarate |
Imidapril hydrochloride |
Irbesartan |
Irbesartan/amlodipine besilate |
Irbesartan/trichlormethiazide |
Enalapril maleate |
Olmesartan medoxomil |
Olmesartan medoxomil/
azelnidipine |
Captopril |
Candesartan cilexetil |
Candesartan cilexetil/
amlodipine besilate |
Candesartan cilexetil/
hydrochlorothiazide |
Temocapril hydrochloride |
Delapril hydrochloride |
Telmisartan |
Telmisartan/amlodipine besilate |
Telmisartan/amlodipine besilate/hydrochlorothiazide |
Telmisartan/hydrochlorothiazide |
Trandolapril |
Valsartan |
Valsartan/amlodipine besilate |
Valsartan/cilnidipine |
Valsartan/hydrochlorothiazide |
Benazepril hydrochloride |
Perindopril erbumine |
Lisinopril hydrate |
Losartan potassium |
Losartan potassium/
hydrochlorothiazide |
Sacubitril valsartan sodium hydrate |
|
Mesalazine |
|
|
PMDSI No. 401 |
Mesalazine |
Zinc acetate hydrate |
|
|
PMDSI No. 401 |
Zinc acetate hydrate |
Leflunomide |
|
|
- |
Ampicillin hydrate |
|
|
- |
Ampicillin sodium |
- |
Ampicillin hydrate/
cloxacillin sodium hydrate |
|
- |
Ampicillin sodium/
cloxacillin sodium hydrate |
- |
Ioversol |
|
|
- |